2. Search Result
Search Result
Results for "

macular degeneration

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

4

Peptides

9

Inhibitory Antibodies

5

Natural
Products

8

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116098
    Anecortave desacetate

    AL-4940

    		 Biochemical Assay Reagents Cancer
    Anecortave desacetate (AL-4940) is an angiogenesis inhibitor. Anecortave is indicated for the study of exudative (wet) age-related macular degeneration as well as retinal tumors .
    Anecortave desacetate
  • HY-P99629
    Galegenimab

    FHTR 2163; RG 6147; RO 7171009

    		 Ser/Thr Protease Neurological Disease
    Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research .
    Galegenimab
  • HY-P3204
    POT-4
    1 Publications Verification

    AL-78898A

    		 Complement System Metabolic Disease
    POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research
    POT-4
  • HY-114653
    SRPIN803

    		Casein Kinase SRPK Cancer
    SRPIN803 is a potent CK2 and SRPK1 dual inhibitor, with IC50s of 203 nM and 2.4 μM, respectively. SRPIN803 exhibits antiangiogenic activity. SRPIN803 can be used for the research of age-related macular degeneration .
    SRPIN803
  • HY-P99576
    Tarcocimab

    OG1953

    		 VEGFR Others
    Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
    Tarcocimab
  • HY-110195
    Smurf1-IN-A01
    1 Publications Verification

    A01

    		 HSP Interleukin Related MyD88 NF-κB Estrogen Receptor/ERR Others Cancer
    Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .
    Smurf1-IN-A01
  • HY-136788
    ALK4290

    AKST4290

    		 CCR Neurological Disease Inflammation/Immunology
    ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3 . ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism .
    ALK4290
  • HY-136788A
    ALK4290 dihydrochloride

    AKST4290 dihydrochloride

    		 CCR Inflammation/Immunology
    ALK4290 dihydrochloride (AKST4290 dihydrochlorid) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3 . ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism .
    ALK4290 dihydrochloride
  • HY-P3204A
    POT-4 TFA

    AL-78898A TFA

    		 Complement System Metabolic Disease
    POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research .
    POT-4 TFA
  • HY-163690
    HTRA1-IN-1

    		Ser/Thr Protease Inflammation/Immunology
    HTRA1-IN-1 (Compound 17) is a selective inhibitor for serine protease high temperature requirement A serine peptidase 1 (HTRA1), with IC50 of 13 nM. HTRA1-IN-1 is potential for ameliorating HTRA1-related diseases, such as age-related macular degeneration (AMD), osteoarthritis, and rheumatoid arthritis .
    HTRA1-IN-1
  • HY-106429
    OT-551 free base

    		Others Others
    OT-551 (free base) is a lipophilic, disubstituted hydroxylamine with antioxidant properties. OT-551 can be used as an eye drop and can be converted by intraocular esterases to its active metabolite, Tempol-H (TP-H). OT-551 can be utilized in geographic atrophy and macular degeneration research .
    OT-551 free base
  • HY-P99298
    Lampalizumab

    RG 7417; TNX 234; Anti-CFD Recombinant Antibody

    		 Complement System Inflammation/Immunology
    Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
    Lampalizumab
  • HY-P99116
    Faricimab

    RG7716

    		 VEGFR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
    Faricimab
  • HY-P9951A
    Ranibizumab (anti-VEGF)

    RG-6321 (anti-VEGF)

    		 VEGFR Cardiovascular Disease
    Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
    Ranibizumab (anti-VEGF)
  • HY-19720
    Emixustat

    ACU-4429

    		 Others Metabolic Disease
    Emixustat is an orally active RPE65 inhibitor with an IC50 value of 4.4 nM. Emixustat is also a visual cycle modulator, capable of regulating visual cycle activity by inhibiting retinol isomerization, and holds potential for studying vision disorders such as age-related macular degeneration (AMD) .
    Emixustat
  • HY-P99905
    Efdamrofusp alfa

    		VEGFR Cardiovascular Disease Neurological Disease
    Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .
    Efdamrofusp alfa
  • HY-19720A
    Emixustat hydrochloride

    ACU-4429 hydrochloride

    		 Others Metabolic Disease
    Emixustat (ACU-4429) hydrochloride is an orally active RPE65 inhibitor with an IC50 value of 4.4 nM. Emixustat hydrochloride is also a visual cycle modulator, capable of regulating visual cycle activity by inhibiting retinol isomerization, and holds potential for studying vision disorders such as age-related macular degeneration (AMD) .
    Emixustat hydrochloride
  • HY-147080
    Avacincaptad pegol sodium

    ARC1905

    		 Complement System Others
    Avacincaptad pegol (ARC1905) sodium is a 40KDa PEG-conjugated aptamer. Avacincaptad pegol sodium targets complement factor 5 (C5), inhibits the cleavage of C5 into C5a and C5b, limits inflammatory stimulation and complement membrane attack complex (MAC), and is used to study age-related macular degeneration (AMD). Avacincaptad pegol sodium limits irregular cell apoptosis by targeting downstream factors in the complement cascade while preserving the early steps of the complement system. Avacincaptad pegol sodium treats Geographic atrophy (GA) mice .
    Avacincaptad pegol sodium
  • HY-P3252A
    Pegcetacoplan acetate

    		Complement System Inflammation/Immunology
    Pegcetacoplan acetate is a pegylated complement C3 inhibitor peptide. Pegcetacoplan acetate acts by binding with complement component 3 (C3) and its activation fragment C3b. Pegcetacoplan acetate can be used for the research of complement-mediated diseases, including age-related macular degeneration, C3 glomerulopathy, Geographic atrophy (GA) and autoimmune haemolytic anaemia .
    Pegcetacoplan acetate
  • HY-16467
    Squalamine lactate

    MSI-1256F

    		 Bacterial Infection Cardiovascular Disease Cancer
    Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.
    Squalamine lactate
  • HY-P99402
    Rinucumab

    REGN 2176

    		 PDGFR Metabolic Disease
    Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .
    Rinucumab
  • HY-15492A
    AG-13958 (mono(hydrochloride))

    AG-013958 monohydrochloride

    		 VEGFR Cardiovascular Disease
    AG-13958 monohydrochloride, a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .
    AG-13958 (mono(hydrochloride))
  • HY-150069
    UBX1325

    		Bcl-2 Family Apoptosis Metabolic Disease
    UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .
    UBX1325
  • HY-15492
    AG-13958
    1 Publications Verification

    AG-013958

    		 VEGFR Cardiovascular Disease
    AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .
    AG-13958
  • HY-109561
    Pegaptanib sodium

    EYE001; NX1838

    		 VEGFR Metabolic Disease Inflammation/Immunology
    Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .
    Pegaptanib sodium
  • HY-158821
    ISTH0036

    		TGF-beta/Smad Others
    ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), can be use in the study of primary open angle glaucoma (POAG), and wet age-related macular degeneration.
    ISTH0036
  • HY-158821A
    ISTH0036 sodium

    		TGF-beta/Smad Others
    ISTH0036 sodium, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), can be use in the study of primary open angle glaucoma (POAG) , and wet age-related macular degeneration.
    ISTH0036 sodium
  • HY-163403
    VEGFR-2-IN-43

    		VEGFR Cardiovascular Disease Cancer
    VEGFR-2-IN-43 (compound 16) is an orally active inhibitor of VEGFR2, with an IC50 of 39.91 μM. VEGFR-2-IN-43 can be used for wet age-related macular degeneration (w-AMD) disease research .
    VEGFR-2-IN-43
  • HY-153484A
    Bevasiranib sodium

    		VEGFR Small Interfering RNA (siRNA) Others
    Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
    Bevasiranib sodium
  • HY-153484
    Bevasiranib

    		VEGFR Small Interfering RNA (siRNA) Others
    Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
    Bevasiranib
  • HY-116312
    8-CPT-2'-O-Me-cAMP

    		Ras Cardiovascular Disease
    8-CPT-2'-O-Me-cAMP is a Rap1 activator. 8-CPT-2'-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration .
    8-CPT-2'-O-Me-cAMP
  • HY-153183
    Lp-PLA2-IN-12

    		Phospholipase Cardiovascular Disease Neurological Disease
    Lp-PLA2-IN-12 (compound 19) is an Lp-PLA2 inhibitor. Lp-PLA2-IN-12 can be used for the study of neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular disease including atherosclerosis .
    Lp-PLA2-IN-12
  • HY-B0146
    Verteporfin
    Maximum Cited Publications
    167 Publications Verification

    CL 318952

    		 YAP Apoptosis Autophagy Cancer
    Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .
    Verteporfin
  • HY-108801
    Aflibercept

    VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

    		 VEGFR Cardiovascular Disease Metabolic Disease Cancer
    Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
    Aflibercept
  • HY-108801A
    Aflibercept (VEGF Trap)

    		VEGFR Cardiovascular Disease Metabolic Disease Cancer
    Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
    Aflibercept (VEGF Trap)
  • HY-113127
    L-Tryptophanamide

    		Others Others
    L-Tryptophanamide is a compound discovered in wet age-related macular degeneration research, which has activities related to affecting retinal cell proliferation, apoptosis, necrosis and angiogenesis. In in vitro experiments, L-Tryptophanamide affects the proliferation, apoptosis and necrosis of human retinal pigment epithelial cells, and promotes tube formation and migration of human retinal endothelial cells.
    L-Tryptophanamide
  • HY-128973
    Pyropheophorbide-a

    		Reactive Oxygen Species Cancer
    Pyropheophorbide-a (Ppa) is a photosensitizer used in photodynamic therapy (PDT) for tumors. Pyropheophorbide-a exhibits phototoxic effects on tumor cells, such as cervical cancer cells, and also has anti-lipogenesis activity. Pyropheophorbide-a shows potential for research in the fields of cancer and age-related macular degeneration (AMD). Pyropheophorbide-a derivatives also demonstrate inhibitory activity against tumor cells .
    Pyropheophorbide-a
  • HY-153560
    Lp-PLA2-IN-14

    		Phospholipase Neurological Disease
    Lp-PLA2-IN-14 (Compound 19) is an Lp-PLA2 inhibitor with a pIC50 of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like .
    Lp-PLA2-IN-14
  • HY-153903
    RASP-IN-1

    		Others Others
    RASP-IN-1 (compound A) is a lipophili ccompound used for macular degeneration inhibition. RASP-IN-1 is biologically active in the retina of the rabbit's eye. Thirty minutes after IP treatment with 14C-RASP-IN-1 (10 mg/kg)，the Cmax amount of 14C-RASP-IN-1 in the posterior eye cup is 14.36 μg/g in mice model .
    RASP-IN-1
  • HY-N6947
    Lutein
    2 Publications Verification

    Xanthophyll

    		 Endogenous Metabolite Apoptosis Reactive Oxygen Species Neurological Disease Inflammation/Immunology
    Lutein (Xanthophyll) is a carotenoid with reported anti-inflammatory properties. A large body of evidence shows that lutein has several beneficial effects, especially on eye health . Lutein exerts its biological activities, including anti-inflammation, anti-oxidase and anti-apoptosis, through effects on reactive oxygen species (ROS) . Lutein is able to arrive in the brain and shows antidepressant-like and neuroprotective effects. Lutein is orally active .
    Lutein
  • HY-B0146R
    Verteporfin (Standard)

    CL 318952 (Standard)

    		 YAP Apoptosis Autophagy Cancer
    Verteporfin (Standard) is the analytical standard of Verteporfin. This product is intended for research and analytical applications. Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .
    Verteporfin (Standard)
  • HY-148370
    IONIS-FB-LRx

    RG6299

    		 Complement System Others
    IONIS-FB-LRx is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx effectively reduces circulating levels of CFB. IONIS-FB-LRx can be used for geographic atrophy (GA) research .
    IONIS-FB-LRx
  • HY-148370A
    IONIS-FB-LRx sodium

    RG6299 sodium

    		 Complement System Others
    IONIS-FB-LRx sodium is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx sodium effectively reduces circulating levels of CFB, and can be used for geographic atrophy (GA) research .
    IONIS-FB-LRx sodium
  • HY-161115
    NR2E3 agonist 1

    		Others Inflammation/Immunology
    NR2E3 agonist 1 (Compound 11a) is a small molecule agonist of the photoreceptor-specific nuclear receptor (NR2E3) with an EC50 value of less than 200 nM. NR2E3 agonist 1 can be used in retinitis pigmentosa research .
    NR2E3 agonist 1
  • HY-162904
    BPU17

    		Others Cardiovascular Disease
    BPU17 binds to PHB1 and causes mild defects in mitochondrial function by defects in the PHB1-PHB2 interaction. This impairment inhibits the SRF/CArG-box-dependent transcription, resulting in the suppression of epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells (RPEs). BPU17 exhibits antifibrotic activity in vivo. BPU17 is promising for research of anti-neovascular age-related macular degeneration (nAMD) agent .
    BPU17
  • HY-112467
    Tivozanib hydrate
    5+ Cited Publications

    AV-951 hydrate; KRN951 hydrate

    		 VEGFR Cancer
    Tivozanib hydrate (AV-951 hydrate; KRN951 hydrate) is the hydrate form of Tivozanib (HY-10977). Tivozanib hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrate exhibits antitumor efficacy .
    Tivozanib hydrate
  • HY-10186
    TG 100801
    1 Publications Verification

    		 VEGFR FGFR PDGFR Src Cancer
    TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    TG 100801
  • HY-10187
    TG 100801 Hydrochloride

    		VEGFR FGFR PDGFR Src Cancer
    TG 100801 Hydrochloride is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    TG 100801 Hydrochloride
  • HY-122129
    Dotriaconta-14,17,20,23,26,29-hexaenoic acid

    		Endogenous Metabolite Metabolic Disease
    Very long chain polyunsaturated fatty acids (VLCPUFA) are present in retina, sperm, and brain. Though little is known of their biosynthesis or functional roles in these tissues, recent studies using the elongation of very long-chain FA-4 protein suggest a unique role for VLCPUFA in retinal development and macular degeneration. Dotriaconta-14,17,20,23,26,29-hexaenoic acid is a C32:6 VLCPUFA whose specific biological actions are largely unknown, but are thought to involve normal photoreceptor cell function in the retina.
    Dotriaconta-14,17,20,23,26,29-hexaenoic acid
  • HY-142778
    Lp-PLA2-IN-10

    		Phospholipase Neurological Disease Metabolic Disease
    Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4) .
    Lp-PLA2-IN-10

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: